Personalized Medicine, Asthma and Allergy, Humanitas Clinical and Research Center, IRCCS, Rozzano, Italy.
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
J Asthma. 2024 Dec;61(12):1593-1600. doi: 10.1080/02770903.2024.2376919. Epub 2024 Jul 23.
In the field of severe asthma, the concept of disease control has recently been integrated by the one of clinical remission. With this new concept, we move on to analyze the efficacy of therapy on multiple parameters simultaneously, starting with the mandatory discontinuation of the systemic glucocorticoids, to which is added the effect on exacerbations, respiratory function, and symptoms control. The Italian severe asthma registry SANI (Severe Asthma Network Italy) drafted criteria for the definition of disease remission, allowing patients to be classified into two groups, partial and complete remission. The greater dynamism of the definition, provided by SANI, allows us to hypothesize its practical use, concerning therapy management of severe asthma patients, starting from the level of remission, with the aim to facilitate the clinical decision on replacement, continuation or modulation of patients' therapy.
在重症哮喘领域,疾病控制的概念最近已被临床缓解所整合。有了这个新概念,我们开始同时分析治疗对多个参数的疗效,首先是强制性停用全身糖皮质激素,然后是对恶化、呼吸功能和症状控制的影响。意大利重症哮喘注册中心 SANI(Severe Asthma Network Italy)制定了疾病缓解的定义标准,允许患者分为两组,部分缓解和完全缓解。SANI 提供的定义更具活力,使我们能够假设其实际用途,涉及重症哮喘患者的治疗管理,从缓解水平开始,旨在促进临床决策,以替代、继续或调整患者的治疗。